Mirae Asset Global Investments Co. Ltd. Buys 63,895 Shares of Illumina, Inc. $ILMN

Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 63,895 shares of the life sciences company’s stock, valued at approximately $17,487,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Illumina in the second quarter valued at approximately $3,374,423,000. Primecap Management Co. CA acquired a new stake in Illumina during the 2nd quarter valued at approximately $617,981,000. Jupiter Topco LLC acquired a new stake in Illumina during the 2nd quarter valued at approximately $358,652,000. WCM Investment Management LLC raised its holdings in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Illumina during the 2nd quarter worth approximately $293,846,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT study, expected to cover about 450,000 people—roughly one in 10 residents. The project extends the company’s work in Singapore into broader clinical and public-health applications, offering a significant showcase for precision medicine. Article
• Neutral Sentiment: The large population covered by the study could create strategic opportunities, but no contract value, revenue timing, or sequencing volume for Illumina was disclosed, so the near-term financial impact is uncertain. Article
• Negative Sentiment: Citigroup raised its price target for ILMN but maintained a “sell” rating, indicating it still sees potential downside. Separately, commentary on the Q3 call cited persistent weakness in research and applied markets, despite strength in clinical sequencing and NovaSeq X placements. Article Article

Insider Buying and Selling at Illumina

In other Illumina news, Director Keith Meister sold 299,336 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $217.96, for a total value of $65,243,274.56. Following the completion of the sale, the director directly owned 1,409,851 shares in the company, valued at approximately $307,291,123.96. This trade represents a 17.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,320,108 shares of company stock worth $288,195,392. 2.90% of the stock is owned by insiders.

Illumina Price Performance

Shares of ILMN opened at $238.21 on Wednesday. The firm has a market cap of $36.02 billion, a PE ratio of 41.00, a price-to-earnings-growth ratio of 3.08 and a beta of 1.46. Illumina, Inc. has a 52-week low of $112.65 and a 52-week high of $309.35. The business’s 50 day moving average price is $249.74 and its two-hundred day moving average price is $177.05. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, topping the consensus estimate of $1.36 by $0.26. The company had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.34 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 5.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ILMN shares. Citigroup upped their price objective on shares of Illumina from $113.00 to $210.00 and gave the company a “sell” rating in a research note on Monday. Guggenheim lifted their target price on shares of Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. TD Cowen boosted their target price on shares of Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a report on Tuesday, October 13th. Canaccord Genuity Group upped their price target on shares of Illumina from $205.00 to $300.00 and gave the company a “hold” rating in a research report on Monday, October 19th. Finally, Barclays increased their price target on Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a report on Wednesday, October 7th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $244.24.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.